Broadly neutralizing antibodies derived from the earliest COVID-19 convalescents protect mice from SARS-CoV-2 variants challenge

Broadly neutralizing antibodies derived from the earliest COVID-19 convalescents protect mice from SARS-CoV-2 variants challenge

Abstract Coronavirus disease 2019 (COVID-19) was first reported three years ago, when a group of individuals were infected with the original SARS-CoV-2 strain, based on which vaccines were developed. Here, we develop six human monoclonal antibodies (mAbs) from two elite convalescents in Wuhan and sh...

Full description

Bibliographic Details
Main Authors: Qianyun Liu, Haiyan Zhao, Zhiqiang Li, Zhen Zhang, Rui Huang, Mengxue Gu, Ke Zhuang, Qing Xiong, Xianying Chen, Weiyi Yu, Shengnan Qian, Yuzhen Zhang, Xue Tan, Muyi Zhang, Feiyang Yu, Ming Guo, Zhixiang Huang, Xin Wang, Wenjie Xiang, Bihao Wu, Fanghua Mei, Kun Cai, Limin Zhou, Li Zhou, Ying Wu, Huan Yan, Sheng Cao, Ke Lan, Yu Chen
Format: Article
Language:English
Published: Nature Publishing Group 2023-09-01
Series:Signal Transduction and Targeted Therapy
Online Access:https://doi.org/10.1038/s41392-023-01615-0

Internet

https://doi.org/10.1038/s41392-023-01615-0

Similar Items